Hepacaf (Human Hepatitis B Immunoglobulin)

Hepacaf is indicated for the prevention of hepatitis B virus infection in individuals who have been exposed to the virus or are at risk of transmission. It is commonly used in the following situations:

• Post‑exposure prophylaxis for persons with recent hepatitis B exposure.
• Prevention of mother‑to‑child transmission when the newborn is at risk.
• Supplementation for patients with inadequate response to hepatitis B vaccine.
• Protection of immunocompromised patients awaiting active immunization.
• Use in healthcare workers after accidental needle sticks involving hepatitis B‑positive blood.

Side effects of Hepacaf vary in frequency and severity. Common reactions are generally mild and transient, while serious events are rare but require medical attention.

Common

• Mild fever or chills shortly after infusion.
• Localized pain or erythema at the injection site.
• Headache or fatigue within 24 hours.
• Nausea or mild gastrointestinal discomfort.

Serious

• Severe allergic reaction (anaphylaxis) with rash, swelling, or difficulty breathing.
• Acute hemolytic transfusion reaction.
• Thromboembolic events such as deep vein thrombosis.
• Renal impairment or acute kidney injury.
• Persistent high fever or sepsis-like symptoms.

Before administering Hepacaf, several precautions should be considered to ensure safe use. Healthcare providers should assess the following:

• Known hypersensitivity to human immunoglobulins or any excipients.
• History of severe allergic reactions or anaphylaxis.
• Underlying renal or hepatic dysfunction.
• Pregnancy and breastfeeding status, as safety data are limited.
• Concomitant use of immunosuppressive therapies.
• Monitoring for signs of transfusion‑related reactions during and after infusion.

Hepacaf may interact with other medications or biologics, influencing efficacy or safety. Consider the following interaction categories:

Avoid

• Concurrent administration with other blood products containing hepatitis B antibodies without proper monitoring.
• Live vaccines administered within 4 weeks of Hepacaf infusion.

Use with caution

• Immunosuppressants that may alter immune response.
• Anticoagulants, as infusion may affect coagulation parameters.
• Renal‑clearing drugs in patients with compromised kidney function.
• Other immunoglobulin preparations, which could increase risk of hyperviscosity.